Prevention and management of COPD in China: Successes and major challenges

The Lancet Respiratory Medicine

Volumn 4, Issue 6, 2016, Pages 428-430

  Guan, Wei Jie ^a   Ran, Pi Xin ^a   Zhong, Nan Shan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOCISTEINE; CARBON MONOXIDE; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; NITROGEN DIOXIDE; SULFUR DIOXIDE; BRONCHODILATING AGENT;

AIR QUALITY; BIOMASS; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; EARLY DIAGNOSIS; EXERCISE TOLERANCE; EXPIRATORY FLOW; HEALTH CARE SYSTEM; HUMAN; LUNG FUNCTION; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NOTE; PARTICULATE MATTER; PATHOGEN LOAD; PRIORITY JOURNAL; QUALITY OF LIFE; RURAL AREA; URBAN AREA; ADULT; AGED; AIR POLLUTANT; DISEASE MANAGEMENT; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIMARY PREVENTION; PROCEDURES; RESPIRATORY CARE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SMOKING;

ADULT; AGED; AIR POLLUTANTS; BRONCHODILATOR AGENTS; CHINA; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRIMARY PREVENTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84966770545     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30092-3     Document Type: Note

References (12)

1. Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease. A large, population-based survey. Am J Respir Crit Care Med 2007, 176:753-760.
2. Zhou Y, Wang C, Yao W, et al. COPD in Chinese nonsmokers. Eur Respir J 2009, 33:509-518.
3. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007, 62:889-897.
4. Zhou YM, Chen SY, Tian J, et al. Development and validation of a chronic obstructive pulmonary disease screening questionnaire in China. Int J Tuberc Lung Dis 2013, 17:1645-1651.
5. Cui J, Zhou YM, Tian J, et al. A discriminant function model as an alternative method to spirometry for COPD screening in primary care settings in China. J Thorac Dis 2012, 4:594-600.
6. Tian J, Zhou Y, Cui J, et al. Peak expiratory flow as a screening tool to detect airway obstruction in a primary health care setting. Int J Tuberc Lung Dis 2012, 16:674-680.
7. Zhou Y, Hu G, Wang D, et al. Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial. BMJ 2010, 341:c6387.
8. Zhou Y, Zou Y, Li X, et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med 2014, 11:e1001621.
9. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008, 371:2013-2018.
10. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2016) Global Initiative for Chronic Obstructive Lung Disease, (accessed April 19, 2016). http://www.goldcopd.org/uploads/users/files/WatermarkedGlobal%20Strategy%202016(1).pdf.
11. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005, 365:1552-1560.
12. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014, 2:187-194.